comparemela.com

Latest Breaking News On - Aniz girach - Page 1 : comparemela.com

SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer

/PRNewswire/ SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of gene therapies, is pleased to announce the.

Wills eye hospitalUnited statesSan franciscoComunidad autonoma de catalunaOcriplasmin jetreaMiquel vila perellAniz girachPrnewswire splicebioEli lillyClinical development at alcon laboratoriesGlobal head of ophthalmology at merck coProtein splicingChief medicalMedical retinaGenetic therapyGlobal head

Sensorion Reports Full-Year 2022 Financial Results and Business Update

CTA filing for OTOF-GT planned for Q2 2023 Presented new preclinical data supporting continued progress of OTOF-GT, and potential for safe and efficient clinical translation of gene therapy

France generalDennis riedlNawal ouzrenBiolabs ptyDavid lawrenceAniz girachInstitut pasteurMatthew cole jessica hodgsonHearing institute institutBoards of enterobiotixGood laboratory practiceResearch developmentInternational media relationsCochlear limitedEuropean medicine agencyGood laboratory practices

Key Topics Not to be Missed at the Ophthalmic Drugs Conference

SAE Media Group reports: join ophthalmic professionals for the Ophthalmic Drugs Conference this November.

United kingdomCity ofCatherine wymanMagali taielMarion munkPearse keaneAndrew gibbonsDaniela ferraraPeter morgan warrenAniz girachGensight biologicsGenentech rocheNaj sharifDaniel chungSimi sapalBayer pharmaceuticals

Developments in Gene Therapy for Ocular Diseases

SAE Media Group reports: The Ophthalmic Drugs Conference will be focusing on developments in Gene Therapy for Ocular Diseases

United statesUnited kingdomCity ofAndrew gibbonsMagali taielGensight biologicsAniz girachDaniel chungSimi sapalUniversity college londonSsae media groupMedia group conferencesMedia groupTechnology partnership celaneseDevelopment of lumevoq gene therapyOphthalmic drugs conference

Sensorion Full-Year 2021 Financial Results and Business Highlights - Press Release

Accelerating development of the OTOF-GT and GJB2-GT gene therapy programs in collaboration with Institut Pasteur Advancing SENS-401 joint clinical dev

Nawal ouzrenScottd myersInstitut pasteurCovis pharmaEdwin mosesCochlear limitedHearing institute institutMaster research agreementCochlear ltdEuropean medicines agencyResearch developmentAssociation for researchCisplatin induced ototoxicityAniz girachIndependent boardNatural history study

vimarsana © 2020. All Rights Reserved.